EI
HRMY icon

EAM Investors’s Harmony Biosciences HRMY Stock Holding History

EAM Investors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,738
Closed -$1.31M – 310
2022
Q4 		$1.31M Buy
+23,738
New +$1.31M 0.27% 174
2022
Q3 		– Sell
-21,276
Closed -$1.04M – 292
2022
Q2 		$1.04M Sell
21,276
-36,064
-63% -$1.62M 0.25% 187
2022
Q1 		$2.79M Buy
+57,340
New +$2.34M 0.52% 56

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM Investors's HRMY Position: Q1 2023 in Review

EAM Investors sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 23,738 shares — an estimated $1.31M sold.

EAM Investors first reported a position in HRMY in Q1 2022 and held it in 3 quarters. The position peaked at $2.79M in Q1 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

  • EAM Investors reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
  • EAM Investors sold 23,738 Harmony Biosciences shares in Q1 2023, an estimated $1.31M.
  • EAM Investors first reported a position in Harmony Biosciences in Q1 2022 and held it in 3 quarters.
  • EAM Investors's Harmony Biosciences position peaked at $2.79M in Q1 2022.
  • 217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.